Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347058 · ClinicalTrials.gov registry record · NA
Immunotherapy & Me
A NA study, sponsored by Cancer Support Community, Research and Training Institute, Philadelphia.
- Completed
- Registry status
- NA
- Development phase
- 134
- Enrollment target
NCT03347058: Completed NA study, sponsored by Cancer Support Community, Research and Training Institute, Philadelphia.
NCT03347058 is a NA study that has completed, run by Cancer Support Community, Research and Training Institute, Philadelphia. The registered enrollment target is 134 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03347058, a NA study, has completed, sponsored by Cancer Support Community, Research and Training Institute, Philadelphia.
- COMPLETED
- Registry status
- NA
- Development phase
- 134 participants
- Enrollment target
Study Summary
Immunotherapy \& Me is a pilot study to determine patient and provider needs around immunotherapy treatment, and to determine the most meaningful resources to improve patient outcomes and decrease cost. Specifically, this study aims: 1. To determine whether layering in customizable resources at the point-of-care that offer healthcare providers care-management tools to give their immunotherapy patients leads to changes in (a) patients' knowledge, attitudes, and health behaviors (including self-reported measures of self-efficacy and empowerment, cancer-related distress, quality of life, and satisfaction with the programs offered) and (b) improved clinical outcomes (including decreased hospital admissions, decreased hospital readmissions, and decreased costs associated with hospitalizations). 2. To successfully integrate the Immunotherapy \& Me program within oncology practices to provide a model framework for dissemination across other care providers. Once success is demonstrated, a turn-key model of immunotherapy patient support can be expanded to other oncology care systems.
Primary Outcome
Cancer-related distress
Interventions
- OTHER Supportive programming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2021-03-31 |
| Phase | NA |
What the finished NCT03347058 record still lists
NCT03347058 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Supportive programming is the first listed.
NCT03347058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03347058 about?
NCT03347058 is a clinical study titled "Immunotherapy & Me". Immunotherapy \& Me is a pilot study to determine patient and provider needs around immunotherapy treatment, and to determine the most meaningful resources to improve patient outcomes and decrease cost. Specifically, this study aims: 1. To determine whether layering in customizable resources at the...
What is the current status of trial NCT03347058?
This trial is currently completed. It is a NA study. The enrollment target is 134 participants. The study started on 2017-12-01. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03347058?
The interventions under investigation include: Supportive programming (OTHER).
Who is sponsoring clinical trial NCT03347058?
This trial is sponsored by Cancer Support Community, Research and Training Institute, Philadelphia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03347058's enrollment target sits among peer trials
134 728th of 2000 higher than 1,272 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI